Protagonist Therapeutics
PTGX
PTGX
272 hedge funds and large institutions have $3.92B invested in Protagonist Therapeutics in 2025 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 119 increasing their positions, 77 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
1% less funds holding
Funds holding: 274 → 272 (-2)
12% less call options, than puts
Call options by funds: $18.4M | Put options by funds: $20.8M
Holders
272
Holding in Top 10
14
Calls
$18.4M
Puts
$20.8M
Top Buyers
| 1 | +$119M | |
| 2 | +$59.4M | |
| 3 | +$41.4M | |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$35.2M |
| 5 |
Holocene Advisors
New York
|
+$29.3M |
Top Sellers
| 1 | -$21.3M | |
| 2 | -$21M | |
| 3 | -$18.8M | |
| 4 |
AGP
Artia Global Partners
Miami,
Florida
|
-$17.2M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$15.2M |
